Detalhe da pesquisa
1.
Upadacitinib monotherapy improves patient-reported outcomes in rheumatoid arthritis: results from SELECT-EARLY and SELECT-MONOTHERAPY.
Rheumatology (Oxford)
; 60(7): 3209-3221, 2021 07 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-33313898
2.
Canakinumab in patients with systemic juvenile idiopathic arthritis and active systemic features: results from the 5-year long-term extension of the phase III pivotal trials.
Ann Rheum Dis
; 77(12): 1710-1719, 2018 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-30269054
3.
Safety of Tofacitinib in the Treatment of Rheumatoid Arthritis in Latin America Compared With the Rest of the World Population.
J Clin Rheumatol
; 23(4): 193-199, 2017 Jun.
Artigo
em Inglês
| MEDLINE | ID: mdl-28145906
4.
Treatment of early rheumatoid arthritis in a multinational inception cohort of Latin American patients: the GLADAR experience.
J Clin Rheumatol
; 18(7): 327-35, 2012 Oct.
Artigo
em Inglês
| MEDLINE | ID: mdl-23047532
5.
Upadacitinib in patients from China, Brazil, and South Korea with rheumatoid arthritis and an inadequate response to conventional therapy.
Int J Rheum Dis
; 24(12): 1530-1539, 2021 Dec.
Artigo
em Inglês
| MEDLINE | ID: mdl-34779576
6.
High Levels of Polypharmacy in Rheumatoid Arthritis-A Challenge Not Covered by Current Management Recommendations: Data From a Large Real-Life Study.
J Pharm Pract
; 34(3): 365-371, 2021 Jun.
Artigo
em Inglês
| MEDLINE | ID: mdl-31451091
7.
A comparative study of PF-06438179/GP1111 (an infliximab biosimilar) and reference infliximab in patients with moderate to severe active rheumatoid arthritis: A subgroup analysis.
Int J Rheum Dis
; 23(7): 876-881, 2020 Jul.
Artigo
em Inglês
| MEDLINE | ID: mdl-32476277
8.
Long-term Efficacy, Safety, and Immunogenicity of the Infliximab (IFX) Biosimilar, PF-06438179/GP1111, in Patients with Rheumatoid Arthritis After Switching from Reference IFX or Continuing Biosimilar Therapy: Week 54-78 Data From a Randomized, Double-Blind, Phase III Trial.
BioDrugs
; 34(2): 197-207, 2020 Apr.
Artigo
em Inglês
| MEDLINE | ID: mdl-31939063
9.
Randomised, double-blind, phase III study comparing the infliximab biosimilar, PF-06438179/GP1111, with reference infliximab: efficacy, safety and immunogenicity from week 30 to week 54.
RMD Open
; 5(1): e000876, 2019.
Artigo
em Inglês
| MEDLINE | ID: mdl-30997153
10.
Clinical predictors of remission and low disease activity in Latin American early rheumatoid arthritis: data from the GLADAR cohort.
Clin Rheumatol
; 38(10): 2737-2746, 2019 Oct.
Artigo
em Inglês
| MEDLINE | ID: mdl-31161486
11.
Correction to: Clinical predictors of remission and low disease activity in Latin American early rheumatoid arthritis: data from the GLADAR cohort.
Clin Rheumatol
; 38(10): 2963-2964, 2019 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-31432337
12.
A randomized controlled trial comparing PF-06438179/GP1111 (an infliximab biosimilar) and infliximab reference product for treatment of moderate to severe active rheumatoid arthritis despite methotrexate therapy.
Arthritis Res Ther
; 20(1): 155, 2018 07 27.
Artigo
em Inglês
| MEDLINE | ID: mdl-30053896
13.
Tofacitinib, an oral Janus kinase inhibitor, in patients from Brazil with rheumatoid arthritis: Pooled efficacy and safety analyses.
Medicine (Baltimore)
; 97(31): e11609, 2018 Aug.
Artigo
em Inglês
| MEDLINE | ID: mdl-30075534
14.
Two-year Efficacy and Safety of Subcutaneous Tocilizumab in Combination with Disease-modifying Antirheumatic Drugs Including Escalation to Weekly Dosing in Rheumatoid Arthritis.
J Rheumatol
; 45(4): 456-464, 2018 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-29247149
15.
Prevalence of cardiovascular disease and major risk factors in patients with rheumatoid arthritis: a multinational cross-sectional study.
Clin Rheumatol
; 37(9): 2331-2340, 2018 Sep.
Artigo
em Inglês
| MEDLINE | ID: mdl-29696436
16.
Analysis of infections and all-cause mortality in phase II, phase III, and long-term extension studies of tofacitinib in patients with rheumatoid arthritis.
Arthritis Rheumatol
; 66(11): 2924-37, 2014 Nov.
Artigo
em Inglês
| MEDLINE | ID: mdl-25047021
17.
Subcutaneous tocilizumab versus placebo in combination with disease-modifying antirheumatic drugs in patients with rheumatoid arthritis.
Arthritis Care Res (Hoboken)
; 66(11): 1653-61, 2014 Nov.
Artigo
em Inglês
| MEDLINE | ID: mdl-24942540
18.
The effect of three or six years of denosumab exposure in women with postmenopausal osteoporosis: results from the FREEDOM extension.
J Clin Endocrinol Metab
; 98(11): 4483-92, 2013 Nov.
Artigo
em Inglês
| MEDLINE | ID: mdl-23979955
19.
Five years of denosumab exposure in women with postmenopausal osteoporosis: results from the first two years of the FREEDOM extension.
J Bone Miner Res
; 27(3): 694-701, 2012 Mar.
Artigo
em Inglês
| MEDLINE | ID: mdl-22113951
20.
Lesao immunoproliferativa angiocêntrica: um diagnóstico diferencial com granulomatose de Wegener / Angiocentric immunoproliferative lesion: differential diagnosis with Wegener's granulomatosis
Rev. bras. reumatol
; 33(6): 255-8, nov.-dez. 1993. ilus
Artigo
em Português
| LILACS | ID: lil-169292